The majority of strokes (85%) are caused by acute ischaemia resulting from the blockage of a cerebral artery, leading to a loss of oxygenation in downstream brain tissue, and ultimately causing neuronal cell death and irreversible neurological damage. The remainder are haemorrhagic strokes, caused by intracerebral haemorrhage or subarachnoid haemorrhage. The treatment of ischaemic stroke has been transformed by advances in imaging technology, as well as the emergence of thrombolytic therapy and subsequent mechanical thrombectomy, sometimes facilitating complete recovery. The increasing use of direct oral anticoagulants is preventing stroke in patients with atrial fibrillation. Therapies targeting neuroinflammation after brain ischaemia, such as transplantation of mesenchymal stem cells, are also emerging as a potentially useful treatment option.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
The foramen ovale, an obligatory channel, allows placental oxygenated blood to directly reach the fetal arterial circulation and remains patent in 25% of the adult population.1Â Patency provides a potential gateway for venous emboli to reach the arterial circulation, potentially resulting ...
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
touchCARDIO is delighted to announce that Heart International has received an impressive new Impact Factor of 1.9 in the 2024 Journal Citation Reports (JCR). This achievement marks a notable increase from last year’s Impact Factor of 0.2 and highlights the journal’s growing influence in the cardiology field.
Watch an expert in thrombosis and haemostasis address reversal strategies in patients with direct oral anticoagulant-associated intracranial haemorrhage (DOAC-ICH).
Three experts discuss the management of complications of sickle cell disease, as well as recent advances in therapy.
Watch three experts provide insights on the impact of ICH in patients receiving DOACs, DOAC-ICH reversal agents and optimizing treatment outcomes.
Watch experts in endocrinology and in primary care discuss key considerations for addressing cardiorenal outcomes in patients with CKD/T2D
Cryptogenic stroke (CS) is a brain infarction that cannot be clearly attributed to cardioembolism, large-vessel atherosclerosis or small artery disease, despite extensive clinical evaluation.1Â It represents approximately one-third of all ischaemic strokes worldwide.2Â Stroke represents a major public health crisis, ...
Introduction: Cryptogenic stroke (CS) accounts for 30–40% of all ischaemic strokes and there is substantial evidence to suggest arrhythmogenic cardioembolic involvement following the development of atrial fibrillation (AF). CS related to AF are often devastating, with around 70% mortality or significant disability. ...
Globally, a high proportion (around 25%) of transient ischemic attacks (TIAs) and ischemic strokes are cryptogenic.1,2Â The Trial of ORG 10172 in Acute Stroke Treatment (TOAST) classification defines a cryptogenic stroke as a brain infarction that is not caused by definite cardioembolism, ...
The factor Xa (FXa) inhibitors apixaban, rivaroxaban and edoxaban, together with the thrombin inhibitor dabigatran, are collectively referred to as non-vitamin K antagonist (or direct) oral anticoagulants (NOACs). FXa inhibitors are widely used for stroke prevention in patients with nonvalvular ...
Atrial fibrillation (AF) is one of the most common arrhythmias. It affected 33.5 million people worldwide in 2010, a number that is expected to double by 2050.1Â AF prevalence increases with age, and approximately 25% of individuals aged 40 years or older will develop AF ...
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Register for free to hear about the latest expert-led education, peer-reviewed articles, conference highlights, and innovative CME activities.
Or use a Social Account.
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.